Nantahala Capital Management LLC Buys New Shares in Dyne Therapeutics, Inc. $DYN

Nantahala Capital Management LLC purchased a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 345,062 shares of the company’s stock, valued at approximately $3,609,000. Nantahala Capital Management LLC owned about 0.30% of Dyne Therapeutics at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. lifted its holdings in Dyne Therapeutics by 5.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company’s stock worth $237,000 after buying an additional 1,115 shares during the last quarter. Arizona State Retirement System lifted its holdings in Dyne Therapeutics by 9.2% during the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company’s stock worth $183,000 after buying an additional 1,481 shares during the last quarter. E Fund Management Co. Ltd. lifted its holdings in shares of Dyne Therapeutics by 16.2% in the 1st quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company’s stock valued at $144,000 after purchasing an additional 1,923 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Dyne Therapeutics in the 4th quarter valued at about $50,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Dyne Therapeutics by 837.5% in the 1st quarter. GAMMA Investing LLC now owns 2,625 shares of the company’s stock valued at $251,000 after purchasing an additional 2,345 shares during the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $13.49 on Monday. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. The business’s 50 day moving average is $10.45 and its two-hundred day moving average is $11.13. Dyne Therapeutics, Inc. has a 12-month low of $6.36 and a 12-month high of $46.26. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of -3.49 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.02. Research analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox bought 100,000 shares of the company’s stock in a transaction on Monday, July 14th. The shares were bought at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the transaction, the chief executive officer owned 242,179 shares of the company’s stock, valued at approximately $2,206,250.69. This trade represents a 70.33% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 20.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on DYN. JPMorgan Chase & Co. reduced their target price on Dyne Therapeutics from $10.00 to $9.00 and set a “neutral” rating for the company in a report on Tuesday, July 15th. Guggenheim restated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, June 18th. Evercore ISI restated an “outperform” rating on shares of Dyne Therapeutics in a research report on Friday, July 11th. Chardan Capital dropped their price target on Dyne Therapeutics from $50.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, July 29th. Finally, Raymond James Financial upgraded Dyne Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $31.00 to $35.00 in a research report on Monday, August 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $34.07.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.